GlassScriptPhysician profile
Rakesh R Patel
NPI 1386629699
$187,229.29
in general payments reported to CMS, 2019-2025
74 companies · $2,182 in 2025
The $2,182 reported for 2025 was more than what 78% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $131K · 2020: $34K · 2021: $5,521 · 2022: $8,319 · 2023: $3,858 · 2024: $1,939 · 2025: $2,182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,894 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,894.49 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $124,497.88 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $14,288.27 | 2019-2023 | Steglatro, Steglujan |
| Sanofi-Aventis U.S. LLC | $9,637.32 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $8,952.81 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $8,710.79 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $5,855.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Eli Lilly and Company | $4,045.76 | 2019-2021 | |
| Mannkind Corporation | $2,068.19 | 2019-2025 | Afrezza |
| Abbott Laboratories | $874.41 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $584.84 | 2019-2025 | Evenity, Prolia, Tepezza |
| Dexcom, INC. | $560.17 | 2019-2023 | Dexcom G6 Transmitter |
| Cequr Corporation | $542.38 | 2022-2025 | Cequr Simplicity |
| Novartis Pharmaceuticals Corporation | $475.92 | 2022-2025 | |
| Intuity Medical INC | $466.58 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Senseonics, Incorporated | $395.00 | 2019-2020 |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $364.70 | 2019-2024 | Omnipod |
| Corcept Therapeutics | $335.76 | 2019-2025 | Korlym |
| Ascensia Diabetes Care US INC. | $295.11 | 2022-2025 | |
| Radius Health, INC. | $291.17 | 2019-2025 | Tymlos |
| Janssen Pharmaceuticals, INC | $289.14 | 2019 | |
| Astellas Pharma US INC | $275.10 | 2023-2025 | Veozah |
| Tandem Diabetes Care, INC. | $223.78 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $220.34 | 2023-2025 | Mazor X System, Minimed 780g |
| Alexion Pharmaceuticals, INC. | $198.83 | 2019-2025 | Strensiq |
| Xeris Pharmaceuticals, INC. | $193.33 | 2022-2025 | Gvoke Hypopen |
| Zealand Pharma US, INC. | $187.46 | 2020-2022 | |
| Ibsa Pharma INC. | $181.51 | 2019-2024 | Tirosint, Licart, Tirosint |
| Valeritas, INC. | $160.84 | 2019 | |
| Amarin Pharma, INC. | $160.11 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $155.78 | 2022-2025 | |
| Abbvie INC. | $130.92 | 2020-2025 | |
| Pfizer INC. | $121.73 | 2022-2024 | |
| Sequel Med Tech, LLC | $97.28 | 2025 | Twiist |
| Neurocrine Biosciences, INC. | $95.76 | 2023-2024 | Ingrezza |
| Esperion Therapeutics, INC. | $84.05 | 2021-2025 | Nexletol |
| Recordati_rare_diseases_inc. | $79.36 | 2023-2025 | Isturisa, Signifor Lar |
| Ascendis Pharma Endocrinology INC | $76.18 | 2025 | Yorvipath |
| Antares Pharma, INC. | $65.83 | 2019-2024 | Xyosted |
| Amryt Pharma Holdings LTD | $62.36 | 2023 | Mycapssa |
| Corium, LLC | $58.43 | 2022-2025 | Azstarys |
| Horizon Therapeutics Plc | $56.82 | 2022 | |
| Kyowa Kirin, INC. | $51.14 | 2024 | Crysvita |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.87 | 2025 | Caplyta |
| Allergan, INC. | $43.44 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $42.08 | 2019-2024 | Unithroid |
| Apollo Endosurgery US INC | $41.86 | 2023 | Overstitch Endoscopic Suturing System |
| Currax Pharmaceuticals LLC | $41.01 | 2022-2024 | Contrave |
| Medtronic Minimed, INC. | $35.79 | 2019 | |
| Companion Medical, INC. | $35.59 | 2019-2020 | |
| Beta Bionics, INC. | $34.00 | 2023-2024 | Ilet Bionic Pancreas |
| Vivus LLC | $32.74 | 2021-2022 | |
| Tolmar, INC. | $30.01 | 2025 | Jatenzo |
| Becton, Dickinson and Company | $28.45 | 2019 | |
| Embecta Corp. | $28.40 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Madrigal Pharmaceuticals | $26.73 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $24.45 | 2022 | |
| Brainsway USA INC | $23.96 | 2024 | Brainsway Deep Tms System |
| Echosens North America, INC. | $23.78 | 2025 | Fibroscan |
| Averitas Pharma INC. | $20.82 | 2024 | Qutenza |
| Exact Sciences Corporation | $20.16 | 2024 | Cologuard Collection Kit |
| Ultragenyx Pharmaceutical INC. | $20.09 | 2023 | Crysvita |
| Alvogen INC | $16.49 | 2025 | Teriparatide |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.45 | 2024 | Cycloset |
| Supernus Pharmaceuticals, INC. | $16.12 | 2025 | Qelbree, Tlando, Xyosted |
| Btg International INC. | $15.52 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $14.78 | 2021 | |
| Eisai INC. | $14.37 | 2019 | |
| Recor Medical INC | $13.61 | 2025 | Paradise Ultrasound Renal Denervation System |
| Regeneron Healthcare Solutions, INC. | $13.29 | 2019 | |
| Halozyme INC | $13.02 | 2023 | |
| Aytu Biopharma, INC. | $12.50 | 2019 | |
| Theracosbio, LLC | $10.71 | 2024 | Brenzavvy |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,613.42 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.